Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials
JAMA Netw Open 7(8):e2423385 Zhou J, Huang W, Xie Y, Shen H, Liu M, Wu X (2025) Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database
There is also increased risk of cholelithiasis although stone formation may be more related to the rapid weight loss seen while on the medication than the medication itself
March 2, 2026: Gastrointestinal Lawsuits Involving Trulicity, Other GLP-1s Increase in March Eli Lilly and one other drug company are facing 3,363 lawsuits in a consolidated MDL, in which plaintiffs accuse the companies of failing to warn patients about the gastrointestinal risks of taking Trulicity and other GLP-1s
The FDA advisory on GLP-1s specifically mentions medullary thyroid cancer